Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance Three Additional Oncology-Targeting Multi-Specific UniAbs into the Clinic

GENEVA & MENLO PARK, Calif. — (BUSINESS WIRE) — Selexis SA and Teneobio, Inc. announced today that they have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs®), a new class of multi-specific biologics.